Given the recent advances in identification, separation and culture of human dendritic cells, it is likely that clinical trials using adoptively transferred cells will play an important role during the next stages in the development of adoptive immunotherapy. The major problem associated with current adoptive therapies (which have been limited to predominantly patients with melanoma and renal cell carcinoma) is that they utilize T- cells which have been expanded from tumor sites where they are admittedly ineffective. Developing new T-cell (and potentially B-cell) reactivity to tumor is a major goal of DC-based strategies. We have designed a clinical protocol in which HLA-A2+ patients with melanoma will have peripheral blood derived dendritic cells cultured with GM-CSF and IL-4 for 5-7 days, pulsed with synthetic melanoma peptides derived from the recently identified MART1/Melan A, gp100, or tyrosinase proteins. More problematic, and the major focus of this application, has been the derivation of tumor antigens from tumors in which relevant T-cell epitopes have not been identified and for the HLA-A2 negative individuals with melanoma. Unanswered questions are those related to the number of tumor cells required, the optimum strategy for delivery (timing, route, method, and type of natural antigen-following in vitro manipulation with cytokines or heat, or route, method, and type of natural antigen-following in vitro manipulation with cytokines or heat, or subsequent to genetic modification), and the appropriate cytokine stimulation. Furthermore, information about the status of dendritic cells in the peripheral blood of cancer patients, the possibility of dendritic cell dysfunction related to factors at the tumor site, and the optimum site, and the optimum means to expand cells in vivo for clinical dysfunction related to factors at the tumor site, and the optimum means to expand cells in vivo for clinical trials (GM-CSF, IL-4, Flt-3L) need to be clarified and defined. We will perform a series of studies designed to investigate these issues in patients with cancer. We will develop the following specific aims:
AIM I. Determine to investigate these issues in patients with cancer. We will develop effective means to derive and deliver tumor antigen peptide or proteins to autologous dendritic cells to elicit tumor-specific T-cells in cancer patients.
AIM II. Use genetic modifications to enhance the function of adoptively transferred DC's by the expression of cytokines or tumor antigens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073743-02
Application #
6103336
Study Section
Project Start
1999-03-10
Project End
1999-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Lohmueller, Jason J; Sato, Shuji; Popova, Lana et al. (2016) Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 6:31740
Zhang, Lixin; Vlad, Anda; Milcarek, Christine et al. (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-35
Sun, Chengqun; Heid, Michelle E; Keyel, Peter A et al. (2013) The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One 8:e61886
Kimura, Takashi; McKolanis, John R; Dzubinski, Lynda A et al. (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6:18-26
Miskov-Zivanov, Natasa; Turner, Michael S; Kane, Lawrence P et al. (2013) The duration of T cell stimulation is a critical determinant of cell fate and plasticity. Sci Signal 6:ra97
Keyel, Peter A; Roth, Robyn; Yokoyama, Wayne M et al. (2013) Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 5:1105-18
Keyel, Peter A; Tkacheva, Olga A; Larregina, Adriana T et al. (2012) Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189:4621-9
Cramer, Daniel W; Finn, Olivera J (2011) Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 23:265-71
Morel, Penelope A; Turner, Michael S (2011) Dendritic cells and the maintenance of self-tolerance. Immunol Res 50:124-9

Showing the most recent 10 out of 90 publications